Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Prof Frederick Fourie to step down: Statement by the Acting Rector, Prof Teuns Verschoor
2008-09-08

Following the announcement by Prof Frederick Fourie that he is stepping down as vice-chancellor of the University of the Free State (UFS), one cannot help but reflect on the momentous contribution he has made to the development of the UFS.

At the time of his appointment as vice-rector in 1999, the UFS was in a financial crisis. There had been three rounds of staff reductions, there were no funds for equipment or the maintenance of buildings and there was a general mood of despair amongst staff.

With his unique style and talents, and against all odds, as acting rector and as rector from 2003, Prof Fourie succeeded in bringing about a financial turnaround that once again brought hope to the staff of the UFS.

Research improved dramatically, inter alia due to the refurbishment of laboratories and the acquisition of world-class research equipment. General campus infrastructure was significantly upgraded and aesthetically improved, making the physical appearance and quality of the campus and example to other universities.

The university structure was critically analysed in all its dimensions and quality assurance projects were launched to improve the overall package of higher education offerings at the UFS.

Another initiative led to the compilation of a transformation plan that was adopted by the management and the UFS Council and that lays the basis for the years ahead.

Through these and countless other initiatives, Prof Fourie has contributed significantly to the establishment of the UFS as a nationally and internationally recognised higher education institution.

Prof Fourie has laid the foundations for the next period of academic growth and development, the value of which will only be appreciated in its full significance in historical perspective.

The UFS is saddened that the high intensity of change management processes has taken its toll on the rector, but is deeply thankful for the legacy that he leaves.

We wish Prof Fourie many productive years ahead and have faith that his remarkable intellect and capabilities will enable him to make many more contributions to the betterment of South African society.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
8 September 2008
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept